New hope for ulcerative colitis patients who failed biologics?

NCT ID NCT07513181

Not yet recruiting Disease control Sponsor: Athos Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called ATH-063 in 120 adults with moderate to severe ulcerative colitis who have not responded to or can no longer use biologic therapies. Participants will receive either the drug or a placebo for 12 weeks to see if it can reduce symptoms and inflammation. The goal is to find a new treatment option for this hard-to-treat group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATH-063 (an experimental drug taken as capsules)
What this could lead to: If successful, this could offer a new treatment option for people with ulcerative colitis who haven't responded to other advanced therapies.
What could go wrong: This is an early Phase 2b study with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease colitis inflammatory bowel disease ulcer disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES INFLAMMATORY BOWEL DISEASES ULCERATIVE COLITIS

Contacts and locations

Locations

Gastroenterology Consultants, P.C.

Roswell, Georgia, 30076, United States
Miami Clinical Research

Miami, Florida, 33155, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.